Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer

S.C. van Nassau, M.J. Bond, I. Scheerman, J. van Breeschoten, R. Kessels, L.B. Valkenburg-van Iersel, H.M. Verheul, T.E. Buffart, L.J. Mekenkamp, V.E. Lemmens, M. Koopman, G.M. Bol*, Clinical EXCITE, EXCITE (From Clinical Trial to Bedside: Triplet Chemotherapy in Metastatic Colorectal Cancer) Study Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numbere2124766
Number of pages14
JournalJama network open
Volume4
Issue number9
DOIs
Publication statusPublished - 10 Sep 2021

Keywords

  • CLINICAL-PRACTICE GUIDELINES
  • FLASH MOB RESEARCH
  • 1ST-LINE TREATMENT
  • OPEN-LABEL
  • FOLFOXIRI
  • REINTRODUCTION
  • MULTICENTER
  • STATEMENT
  • PHASE-3
  • TIME

Cite this